AQP4-IgG阳性视神经脊髓炎谱系疾病由依库珠单抗转换为萨特利珠单抗后出现严重复发
本文报告一名44岁AQP4-IgG阳性视神经脊髓炎谱系疾病女性患者,经硫唑嘌呤、利妥昔单抗治疗控制不佳后启用依库珠单抗获得临床疗效。两年后因发生类风湿关节炎及静脉通路困难,转换为萨特利珠单抗,末次依库珠单抗输注后11周发生严重复发,表现为严重四肢瘫、新发广泛颈髓病灶及胼胝体肿胀性病灶。作者指出,因副作用或不耐受而转换抗补体治疗时应谨慎,存在高复发风险。
要点
- AQP4-IgG阳性NMOSD患者由依库珠单抗转换为萨特利珠单抗后11周发生严重复发。
- 复发表现为严重四肢瘫、新发广泛颈髓病灶及胼胝体肿胀性病灶。
- 作者认为因不耐受或副作用而转换抗补体治疗时应谨慎,因存在高复发风险。
核心结论
- 在临床实践中,因不耐受或副作用而转换抗补体治疗时,应谨慎地转换为另一种NMOSD治疗,因为存在高复发风险。
- 本病例报告提供IV级证据,表明停用依库珠单抗并立即转换为另一种治疗时应谨慎。
研究设计与样本
- 单例病例报告,为无对照的单次观察性研究。
- 患者为44岁女性NMOSD患者,先后接受硫唑嘌呤、利妥昔单抗治疗,疾病未获最佳控制,后启用依库珠单抗并获得临床疗效。
主要发现
- 启用依库珠单抗两年后,因发生类风湿关节炎及静脉通路困难,提议转换为萨特利珠单抗。
- 转换后,在末次依库珠单抗输注后11周发生严重复发。
- 严重四肢瘫与新发广泛颈髓病灶及胼胝体肿胀性病灶相关。
- 患者接受10次甲泼尼龙输注和10次血浆置换治疗,症状出现后20天重新启用依库珠单抗。
- 3个月后观察到轻度改善。
临床怎么用
- 作者认为,因不耐受或副作用而转换抗补体治疗时,应谨慎地转换为另一种NMOSD治疗,因为存在高复发风险。
- 本病例报告提供IV级证据,表明停用依库珠单抗并立即转换为另一种治疗时应谨慎。
局限性
- 本文为单例病例报告,为无对照的单次观察性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Several treatments have been approved for the prevention of attacks in AQP4-IgG+ neuromyelitis optica spectrum disorder (NMOSD). However, because of the rarity of the disease, little is known concerning how to switch from one treatment to another in case of lack of effectiveness or side effects. In this article, we report a severe attack in a patient with NMOSD after switching from eculizumab to satralizumab. METHODS: A 44-year-old woman with NMOSD was treated with azathioprine and then rituximab, without optimal control of the disease. Eculizumab was initiated with clinical efficacy. Two years later, after the onset of rheumatoid arthritis and because of difficult venous access, a switch to satralizumab was proposed. RESULTS: After switching, a severe attack occurred 11 weeks after the last eculizumab infusion. Severe tetraplegia was related to a new extensive cervical lesion associated with a tumefactive lesion of the corpus callosum. The patient was treated with 10 infusions of methylprednisolone and 10 plasma exchanges. Eculizumab was reintroduced 20 days after symptom onset. Three months later, mild improvement was observed. DISCUSSION: In clinical practice, in case of intolerance or side effects, anticomplement therapy should be switched to another NMOSD treatment with caution because of a high risk of relapse. CLASSIFICATION OF EVIDENCE: This case report provides Class IV evidence that eculizumab should be stopped with caution and switched to another treatment immediately. This is a single observational study without controls.
引用
- Maillart E, Dubessy AL, Shor N, et al. Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder. Neurology. 2025. PMID: 39913883. doi:10.1212/WNL.0000000000213399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。